FDA Extends LDT Comment Period

FDA is collecting comments from a range of stakeholders that are interested in what kind of lab-developed testing oversight may be on the horizon before it decides its regulatory strategy.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.